Pomalidomide, a critical drug for treating multiple myeloma and other blood disorders, is produced by leading pharmaceutical manufacturers globally. Renowned companies like Celgene, a Bristol Myers Squibb company, have pioneered its development and distribution. Other trusted manufacturers focus on producing high-quality generic versions, ensuring affordability and accessibility for patients worldwide.